U.S. patent number RE47,121 [Application Number 14/334,294] was granted by the patent office on 2018-11-13 for embolic compositions.
This patent grant is currently assigned to BioCure, Inc.. The grantee listed for this patent is BioCure, Inc.. Invention is credited to Bruktawit T. Asfaw, Hassan Chaouk, Stephen D. Goodrich, Dennis W. Goupil, Troy Holland, Lucas Latini.
United States Patent |
RE47,121 |
Goupil , et al. |
November 13, 2018 |
Embolic compositions
Abstract
Embolic compositions comprising macromers having a backbone
comprising a polymeric backbone comprising units with a 1,2-diol or
1,3-diol structure, such as polyvinyl alcohol, and pendant chains
bearing crosslinkable groups and, optionally, other modifiers. When
crosslinked, the macromers form hydrogels having many properties
advantageous for use as embolic agents to block and fill lumens and
spaces. The embolic compositions can be used as liquid embolic
agents and crosslinked in situ or as preformed embolic articles,
such as microspheres.
Inventors: |
Goupil; Dennis W. (Norcross,
GA), Chaouk; Hassan (Atlanta, GA), Holland; Troy
(Suwanee, GA), Asfaw; Bruktawit T. (Atlanta, GA),
Goodrich; Stephen D. (Norcross, GA), Latini; Lucas
(Norcross, GA) |
Applicant: |
Name |
City |
State |
Country |
Type |
BioCure, Inc. |
Norcross |
GA |
US |
|
|
Assignee: |
BioCure, Inc. (Norcross,
GA)
|
Family
ID: |
26884649 |
Appl.
No.: |
14/334,294 |
Filed: |
July 17, 2014 |
Related U.S. Patent Documents
|
|
|
|
|
|
|
Application
Number |
Filing Date |
Patent Number |
Issue Date |
|
|
10465497 |
Jun 19, 2003 |
|
|
|
|
09804963 |
Jan 13, 2004 |
6676971 |
|
|
|
60188975 |
Mar 13, 2000 |
|
|
|
|
60254697 |
Dec 11, 2000 |
|
|
|
Reissue of: |
12386828 |
Apr 23, 2009 |
8221735 |
Jul 17, 2012 |
|
|
Current U.S.
Class: |
1/1 |
Current CPC
Class: |
C08F
290/00 (20130101); A61B 17/12113 (20130101); C08F
277/00 (20130101); A61L 24/06 (20130101); C08F
8/30 (20130101); A61L 27/34 (20130101); A61P
15/00 (20180101); C08L 51/003 (20130101); A61L
27/16 (20130101); A61L 29/041 (20130101); A61B
17/12122 (20130101); A61P 7/00 (20180101); C08F
261/04 (20130101); A61P 7/04 (20180101); A61B
17/12022 (20130101); A61B 17/12099 (20130101); A61L
27/52 (20130101); A61L 29/085 (20130101); A61L
31/048 (20130101); A61P 35/00 (20180101); C08F
271/02 (20130101); A61L 31/10 (20130101); A61B
17/12186 (20130101); A61B 17/12195 (20130101); C08F
290/14 (20130101); A61B 17/1219 (20130101); C08F
261/00 (20130101); C08F 290/12 (20130101); A61L
27/16 (20130101); A61L 27/34 (20130101); A61B
17/12122 (20130101); A61L 24/0031 (20130101); C08L
51/08 (20130101); A61L 24/0031 (20130101); A61B
17/12195 (20130101); A61L 24/06 (20130101); A61B
17/12113 (20130101); A61B 17/12022 (20130101); A61B
17/1219 (20130101); A61B 17/12186 (20130101); A61B
17/12099 (20130101); A61L 24/06 (20130101); C08L
29/04 (20130101); A61L 27/16 (20130101); C08L
29/04 (20130101); A61L 27/16 (20130101); C08L
29/00 (20130101); A61L 27/34 (20130101); C08L
29/04 (20130101); A61L 27/34 (20130101); C08L
29/00 (20130101); A61L 29/041 (20130101); C08L
29/04 (20130101); A61L 29/041 (20130101); C08L
29/00 (20130101); A61L 29/085 (20130101); C08L
29/04 (20130101); A61L 31/048 (20130101); C08L
29/04 (20130101); A61L 31/10 (20130101); C08L
29/04 (20130101); C08L 51/08 (20130101); C08L
2666/02 (20130101); A61L 2430/36 (20130101); A61L
31/10 (20130101); A61L 27/52 (20130101); A61L
31/048 (20130101); A61L 29/041 (20130101) |
Current International
Class: |
A61K
31/765 (20060101); A61L 27/34 (20060101); A61L
27/16 (20060101); A61L 24/06 (20060101); A61L
24/00 (20060101); A61B 17/12 (20060101); A61L
31/04 (20060101); A61L 31/10 (20060101); A61L
27/52 (20060101); A61L 29/04 (20060101) |
Field of
Search: |
;525/61 |
References Cited
[Referenced By]
U.S. Patent Documents
Foreign Patent Documents
|
|
|
|
|
|
|
730 847 |
|
Sep 1996 |
|
EP |
|
WO 92/21327 |
|
Dec 1992 |
|
WO |
|
WO 92121327 |
|
Dec 1992 |
|
WO |
|
WO 95/09659 |
|
Apr 1995 |
|
WO |
|
WO 97/04656 |
|
Feb 1997 |
|
WO |
|
WO 97/04657 |
|
Feb 1997 |
|
WO |
|
WO 97/04813 |
|
Feb 1997 |
|
WO |
|
WO 97/22371 |
|
Jun 1997 |
|
WO |
|
WO 97/22372 |
|
Jun 1997 |
|
WO |
|
WO 97/27888 |
|
Aug 1997 |
|
WO |
|
WO 98/04312 |
|
Feb 1998 |
|
WO |
|
WO 98/17200 |
|
Apr 1998 |
|
WO |
|
WO 98/17201 |
|
Apr 1998 |
|
WO |
|
WO 99/12577 |
|
Mar 1999 |
|
WO |
|
WO 99/44643 |
|
Sep 1999 |
|
WO |
|
WO 00/09087 |
|
Feb 2000 |
|
WO |
|
WO 00/09088 |
|
Feb 2000 |
|
WO |
|
WO 00/09190 |
|
Feb 2000 |
|
WO |
|
WO 00/09199 |
|
Feb 2000 |
|
WO |
|
WO 00/23054 |
|
Apr 2000 |
|
WO |
|
WO 00/35373 |
|
Jun 2000 |
|
WO |
|
WO 00/45868 |
|
Aug 2000 |
|
WO |
|
WO 00/50103 |
|
Aug 2000 |
|
WO |
|
WO 00/56370 |
|
Sep 2000 |
|
WO |
|
WO 00/56380 |
|
Sep 2000 |
|
WO |
|
WO 00/62827 |
|
Oct 2000 |
|
WO |
|
WO 00/64977 |
|
Nov 2000 |
|
WO |
|
WO 01/16210 |
|
Mar 2001 |
|
WO |
|
WO 01/17574 |
|
Mar 2001 |
|
WO |
|
WO 01/44307 |
|
Jun 2001 |
|
WO |
|
WO 01/55360 |
|
Jun 2001 |
|
WO |
|
WO 01/55360 |
|
Aug 2001 |
|
WO |
|
WO 01/70132 |
|
Sep 2001 |
|
WO |
|
WO 01/70289 |
|
Sep 2001 |
|
WO |
|
WO 01/70290 |
|
Sep 2001 |
|
WO |
|
WO 01/70291 |
|
Sep 2001 |
|
WO |
|
WO 01/72281 |
|
Oct 2001 |
|
WO |
|
WO 02/16443 |
|
Feb 2002 |
|
WO |
|
Other References
Brittain, Analytical Profiles of Drug Substances and Excipients,
vol. 24, p. 434 (1996). cited by applicant .
Chio et al., "Inactivation of Ribonuclease and Other Enzymes by
Peroxidizing Lipids and by Malonaldehyde," Biochemistry, vol. 8,
pp. 2827-2832 (1969). cited by applicant .
Collagen (http://en.wikipedia.org/wiki/Collagen). Accessed Oct. 26,
2015. cited by applicant .
Kinoshita et al., Neuroradiology, vol. 36, pp. 65-68 (1994). cited
by applicant .
Nishi, S. et al., ASAIO Journal M405-M410 (1998). cited by
applicant .
Peptide Bond (http://en.wikipedia.org/wiki/Peptide_bond). Accessed
Oct. 26, 2015. cited by applicant .
Thanoo, B.C. et al., "Preparation and Properties of Barium Sulphate
and Methyl Iothalamate Loaded Poly(vinyl Alcohol) Microspheres as
Radiopaque Particulate Emboli," Journal of Applied Biomaterials,
vol. 2, pp. 67-72 (1991). cited by applicant .
Thanoo, B.C. et al., J. Pharm. Pharmacol., vol. 45, pp. 16-20
(1993). cited by applicant .
Zou, Y.H. et al., vol. 23, No. 6, pp. 330-332 (1989). cited by
applicant.
|
Primary Examiner: Campell; Bruce
Attorney, Agent or Firm: Beard; Collen
Parent Case Text
.Iadd.This application is an application for reissue of U.S. Pat.
No. 8,221,735. U.S. application Ser. No. 14/659,377 is also an
application for reissue of U.S. Pat. No. 8,221,735 and claims
benefit under 35 U.S.C. .sctn. 120 as a continuation reissue
application..Iaddend.
RELATED APPLICATIONS
This application is a Divisional of U.S. Ser. No. 10/465,497, which
was filed on Jun. 19, 2003, now abandoned which is a Divisional of
U.S. Ser. No. 09/804,963, which was filed on Mar. 13, 2001, now
U.S. pat. No. 6,676,971 and claims priority to U.S. Ser. No.
60/188,975 filed on Mar. 13, 2000 and U.S. Ser. No. 60/254,697
filed on Dec. 11, 2000.
Claims
What is claimed is:
1. A method for embolization, comprising the steps: providing a
composition comprising macromers having a polymeric backbone
comprising units with a 1,2-diol or 1,3-diol structure and at least
two pendant chains bearing crosslinkable groups and having the
formula: ##STR00005## in which R is a linear or branched
C.sub.1-C.sub.8 alkylene or a linear or branched C.sub.1-C.sub.12
alkane; R.sub.1 is hydrogen, a C.sub.1-C.sub.6 alkyl, or a
cycloalkyl; R.sub.2 is hydrogen or a C.sub.1-C.sub.6 alkyl; and
R.sub.3 is an olefinically unsaturated electron attracting
copolymerizable radical having up to 25 carbon atoms; delivering
the composition to the intended site of embolization, or upstream
of the intended site; and then crosslinking the macromers to form a
hydrogel; wherein the crosslinkable groups of the macromer are
crosslinkable via free radical polymerization that is redox
initiated; and the composition comprises a first solution
comprising a reductant and a second solution comprising an oxidant
and the macromers are present in either or both solutions.
2. The method of claim 1, wherein the .[.macromere.].
.Iadd.macromer .Iaddend.further comprises pendant modifier
groups.
3. The method of claim 1, further comprising administering an
active agent.
4. The method of claim 3, wherein the active agent is a
chemotherapeutic agent.
5. The method of claim 1, wherein the hydrogel is
biodegradable.
6. The method of claim 1, wherein the composition further comprises
a copolymerizable monomer.
7. The method of claim 1, wherein the method comprises using a
delivery device to deliver the solutions separately and mixing the
solutions to initiate crosslinking.
8. The method of claim 7 wherein the solutions are delivered to the
intended site using a multilumen catheter.
9. The method of claim 8 wherein the solutions are mixed in the
catheter.
10. The method of claim 1, wherein the embolization is used for
treatment of a uterine fibroid, by delivering the embolic
composition to a vessel feeding the fibroid to occlude the
vessel.
11. The method of claim 1, wherein the embolization is used for
treatment of a tumor, by delivering the embolic composition to a
vessel feeding the tumor to occlude the vessel.
12. The method of claim 1, wherein the embolization is used for
treatment of an endoleak by delivering the embolic composition to
seal the endoleak.
13. The method of claim 12, wherein scaling the endoleak comprises
partially or completely filling the aneurysm sac with the embolic
composition.
14. The method of claim 1, wherein the embolization is used for
treatment of an arteriovenous malformation by delivering the
embolic composition to occlude the malformation.
.Iadd.15. The method of claim 1, further comprising delivering an
occlusive device to the intended site of embolization before,
during, or after the embolic composition is
administered..Iaddend.
.Iadd.16. The method of claim 15, wherein the macromers have a
cellular adhesion promoter attached thereto..Iaddend.
.Iadd.17. The method of claim 1, wherein the composition includes a
contrast agent..Iaddend.
.Iadd.18. The method of claim 1, wherein the macromers have a
molecule attached thereto that allows visualization of the formed
hydrogel..Iaddend.
Description
BACKGROUND OF THE INVENTION
The invention relates to compositions for use in embolic agents.
More specifically, the invention relates to compositions including
crosslinkable macromonomers (referred to herein as macromers) that
form hydrogels useful in embolization.
Embolic agents are useful for a variety of bioapplications, such as
occluding blood vessels, occluding other body lumens such as
fallopian tubes, filling aneurysm sacs, as arterial sealants, and
as puncture sealants. Embolization of blood vessels is performed
for a number of reasons, e.g. to reduce blood flow to and encourage
atrophy of tumors, such as in the liver, to reduce blood flow and
induce atrophy of uterine fibroids, for treatment of vascular
malformations, such as arteriovenous malformations (AVMs) and
arteriovenous fistulas (AVFs), to seal endoleaks into aneurysm
sacs, to stop uncontrolled bleeding, or to slow bleeding prior to
surgery.
Gynecologic embolotherapy may be conducted for a variety of
purposes including the treatment of uterine fibroids, the treatment
of postpartum and post cesarean bleeding, the treatment of post
surgical vaginal bleeding, the prevention and/or treatment of
hemorrhage from ectopic pregnancy, prophylactically prior to
myomectomy and in obstetrical patients at high risk for bleeding,
such as those patients with placenta previa, placenta accreta,
uterine fibroids, and twin fetal death.
Abdominal aortic aneurysms (AAA) and thoracic aortic aneurysms
(TAA) are relatively rare but often fatal conditions. Open surgery,
primarily using clips or ligation techniques, has been the
traditional means of treating AAAs and TAAs. Endovascular
techniques, i.e. the placement of a stent graft at the site of the
aneurysm, have become more popular. The currently available stent
graft products, however, are not well matched to the unpredictable
and singular anatomy presented by the aneurysm and its surrounding
vasculature. Often, there are leaks into the excluded aneurysm sac,
termed endoleaks, due to several reasons, including feeder vessels
into the sac, spaces between the stent graft and the vessel wall,
or holes in the stent graft wall. Such endoleaks can cause the
pressure within the aneurysm sac to increase and cause the aneurysm
to further expand and to rupture. Various embolic materials,
including the devices and materials discussed above, have been
placed in the aneurysm sac to induce thrombosis or otherwise to
pack the aneurysm sac to seal the endoleak. Embolic materials are
also used to occlude feeder vessels into the sac. WO 00/56380 to
Micro Therapeutics, Inc. discloses the use of precipitating
polymers and prepolymers such as cyanoacrylate to seal
endoleaks.
Chemoembolotherapy as used herein refers to the combination of
providing mechanical blockage and highly localized, in situ
delivery of chemotherapeutic agents. In the treatment of solid
tumors, the chemotherapeutic agent acts as an adjunct to the
embolization. A known clinical practice is mixing of
chemotherapeutic agents with embolic PVA particles for the delivery
of the drugs at tumor sites. This type of regional therapy may
localize treatment at the site of the tumor, and therefore the
therapeutic dose may be smaller than the effective systemic dose,
reducing potential side effects and damage to healthy tissue.
However, since the chemotherapeutic drug is simply suspended with
the beads there is little or no sustained release.
One type of embolic agent that is commonly used for occluding
vessels is polyvinyl alcohol (PVA) particles. Such particles are
nonspherical and are nonuniform in both size and shape. The
particles are delivered via catheter in the vessel upstream of
their desired placement site. Upon release, the particles are
carried downstream whereupon they eventually lodge in the vessel.
The problems associated with presently available PVA embolic
particles include recanalization of the vessel, which may require
follow up procedures, extensive mixing required to keep the
particles suspended during injection, slow injection times and
blocking of the catheter due to the high friction coefficient (due
to the irregular shape and size of the particles), and
inflammation. Other disadvantages of the use of the presently
available PVA embolizing particles include lack of control as to
where the particles eventually deposit, again due to the size
irregularity. Some particles may continue downstream during
administration and lodge in the vessel at a point past the desired
site of embolization. Some particles may dislodge in the future and
drift downstream.
Another issue with the presently available PVA embolic particles is
that they are generally made using an aldehyde, such as
glutaraldehyde. Such particles must be extracted prior to use, and
may contain amounts of the aldehyde in the final product.
BioSphere Medical, Inc. markets microspheres for embolization made
from acrylic polymer and impregnated with porcine gelatin. An
obvious disadvantage of this product is that it may cause an immune
reaction in patients who are sensitive to collagen or gelatin.
Other types of embolic materials that have been used include solid
structures such as metallic microcoils, expandable balloons, and
expandable materials such as temperature responsive preformed solid
polymers and PVA sponges. Microcoils and balloons are limited to
use in larger vessels and are prone to recanalization. Extrusion
techniques have also been used to deliver extruded polymers to the
intended site.
Liquid embolic agents have been developed, which can be delivered
to the intended site via a catheter or a syringe, whereupon they
solidify to form a solid plug or mass. Temperature responsive
polymers have been proposed as embolic agents, as described in WO
00/45868 to University of California. These polymers are in a
liquid state when delivered to the intended site and harden in
response to the increased temperature of the body.
Another type of liquid embolic agent is compositions containing a
polymer in an organic solvent, wherein the polymer precipitates as
the solvent is displaced by aqueous based body fluids. See, e.g.,
U.S. Pat. No. 6,051,607 to Greff and U.S. Pat. No. 5,925,683 to
Park. A disadvantage of such products is that the polymer may
remain in liquid form for a period of time while the solvent
dissipates. The solvent may not completely dissipate from the
center of the polymer mass, creating a mass with a solid shell and
liquid center. The solvent concentration at the point of injection
may increase to a point where small strings of unsolidified polymer
material may separate from the polymer mass and be carried away in
the blood stream where they can occlude an undesired vascular
location. Moreover, the catheter used to deliver the
polymer/solvent mixture is typically flushed with solvent before
use. This must be done carefully to avoid vascular damage from the
solvent.
Another type of liquid embolic agent is monomers that polymerize
upon exposure to blood, such as cyanoacrylate. See, e.g. U.S. Pat.
No. 6,037,366 to Krall et al. and WO 00/56370 to Micro
Therapeutics, Inc. The conventional cyanoacrylate type embolic
material is injected into the site of an aneurysm with difficulty
because it quickly undergoes curing polymerization in the blood
vessel. The material can be very adhesive and a catheter inserted
into the blood vessel to deliver the material must be extracted at
a stroke as soon as the injection of the material into the site of
disease is completed to avoid the catheter being adhered in place.
Thus, the material is not easy to handle. The injection cannot be
repeated even when the occlusion is imperfect. This embolic
material is further disadvantageous in that it can inflict a grave
stimulus to the wall of the blood vessel and induce a strong
inflammatory reaction.
WO 00/09190 to Incept LLC discloses embolic agents made from two or
more liquid polymers that crosslink when combined. The components
can be combined in situ at the intended site of embolization.
SUMMARY OF THE INVENTION
The invention relates to embolic compositions comprising macromers
having a backbone of a polymer having units with a 1,2-diol and/or
1,3-diol structure. Such polymers include polyvinyl alcohol (PVA)
and hydrolyzed copolymers of vinyl acetate, for example, copolymers
with vinyl chloride, N-vinylpyrrolidone, etc. The backbone polymer
contains pendant chains bearing crosslinkable groups and,
optionally, other modifiers. When crosslinked, the macromers form
hydrogels advantageous for use as embolic agents to block and fill
lumens and spaces.
In one embodiment, the embolic compositions are preformed into
embolic articles before introduction into the body. In another
embodiment, the embolic compositions are used as liquid embolic
agents and formed into a hydrogel in situ.
The embolic compositions can be used for a variety of applications
such as, but not limited to, vascular occlusion for treatment of
tumors or fibroids, occlusion of vascular malformations, such as
arteriovenous malformations (AVM), occlusion of left atrial
appendages, fillers for aneurysm sacs, endoleak sealants, arterial
sealants, puncture sealants, and occlusion of other lumens such as
fallopian tubes.
In one embodiment, the embolic composition forms a permanent
occlusion or mass. In another embodiment, the embolic composition
forms a temporary or reversible (the terms temporary and reversible
are herein used interchangeably) occlusion or mass. Temporary
occlusion may be desired, for example, in treatment of tumors, to
allow for recanalization and reapplication of a chemotherapeutic
agent to the tumor. As another example, temporary occlusion may be
desirable when using the embolic composition for temporary
sterilization. Temporary occlusion can be achieved by using a fully
or partially degradable embolic composition or a composition that
degrades in response to an applied condition, such as a change in
temperature or pH. Occlusion can also be reversed using devices
designed for recanalization.
The processes for using the embolic compositions as liquid embolic
agents include delivering the macromers to the intended site of
embolization, or upstream of the intended site, using a delivery
device such as a catheter or syringe. The macromers are then
crosslinked into a hydrogel, generally upon exposure to a
crosslinking initiator. In one embodiment, the macromers are
dissolved in a biocompatible solution prior to administration. In
one embodiment, the macromers are exposed to the crosslinking
initiator before they are administered to the intended site of
embolization.
DETAILED DESCRIPTION OF THE INVENTION
The term "embolic" or "embolizing" refers to a composition or agent
introduced into a space, a cavity, or the lumen of a blood vessel
or other like passageway that partially or totally fills the space
or cavity or partially or totally plugs the lumen. For example, an
embolic composition can be used for occlusion of a vessel leading
to a tumor or fibroid, occlusion of a vascular malformation, such
as an arteriovenous malformation (AVM), occlusion of a left atrial
appendage, as a filler for an aneurysm sac, as an endoleak sealant,
as an arterial sealant, as a puncture sealant, or for occlusion of
any other lumen such as, for example, a fallopian tube.
As used herein, the term "lumen" is intended to refer to various
hollow organs or vessels of the body, such as veins, arteries,
intestines, fallopian tubes, trachea, and the like.
The invention relates to embolic compositions comprising macromers
having a backbone of a polymer having units with a 1,2-diol and/or
1,3-diol structure and having at least two pendant chains including
a crosslinkable group and optionally pendant chains containing
modifiers. The macromers form a hydrogel when crosslinked. In one
embodiment, the embolic compositions are employed as liquid embolic
agents, meaning that the composition is administered prior to
complete crosslinking of the microliters. In another embodiment,
the embolic compositions are employed as preformed crosslinked
hydrogel articles. The embolic compositions can also be used as a
combination of liquid and preformed compositions.
The embolic compositions can be produced very simply and
efficiently due to a number of factors. Firstly, the starting
materials, such as polyhydroxy polymer backbones, are inexpensive
to obtain or prepare. Secondly, the macromers are stable, so that
they can be subjected to very substantial purification. The
crosslinking can therefore be carried out using a macromer that is
highly pure, containing substantially no unpolymerized
constituents. Furthermore, the crosslinking can be carried out in
purely aqueous solutions. Aldehyde is not required.
I. The Embolic Compositions
The Macromer Backbone
The macromers have a backbone of a polymer comprising units having
a 1,2-diol or 1,3-diol structure, such as polyhydroxy polymers. For
example, polyvinyl alcohol (PVA) or copolymers of vinyl alcohol
contain a 1,3-diol skeleton. The backbone can also contain hydroxyl
groups in the form of 1,2-glycols, such as copolymer units of
1,2-dihydroxyethylene. These can be obtained, for example, by
alkaline hydrolysis of vinyl acetate-vinylene carbonate copolymers.
Other polymeric diols can be used, such as saccharides.
In addition, the macromers can also contain small proportions, for
example, up to 20%, preferably up to 5%, of comonomer units of
ethylene, propylene, acrylamide, methacrylamide, dimethacrylamide,
hydroxyethyl methacrylate, alkyl methacrylates, alkyl methacrylates
which are substituted by hydrophilic groups, such as hydroxyl,
carboxyl or amino groups, methyl acrylate, ethyl acrylate,
vinylpyrrolidone, hydroxyethyl acrylate, allyl alcohol, styrene,
polyalkylene glycols, or similar comonomers usually used.
Polyvinyl alcohols that can be used as macromer backbones include
commercially available PVAs, for example Vinol.RTM. 107 from Air
Products (MW 22,000 to 31,000, 98 to 98.8% hydrolyzed),
Polysciences 4397 (MW 25,000, 98.5% hydrolyzed), BF 14 from Chan
Chun, Elvanol.RTM. 90-50 from DuPont and UF-120 from Unitika. Other
producers are, for example, Nippon Gohsei (Gohsenol.RTM.), Monsanto
(Gelvatol.RTM.), Wacker (Polyviol.RTM.), Kuraray, Deriki, and
Shin-Etsu. In some cases it is advantageous to use Mowiol.RTM.
products from Hoechst, in particular those of the 3-83, 4-88, 4-98,
6-88, 6-98, 8-88, 8-98, 10-98, 20-98, 26-88, and 40-88 types.
It is also possible to use copolymers of hydrolyzed or partially
hydrolyzed vinyl acetate, which are obtainable, for example, as
hydrolyzed ethylene-vinyl acetate (EVA), or vinyl chloride-vinyl
acetate, N-vinylpyrrolidone-vinyl acetate, and maleic
anhydride-vinyl acetate. If the macromer backbones are, for
example, copolymers of vinyl acetate and vinylpyrrolidone, it is
again possible to use commercially available copolymers, for
example the commercial products available under the name
Luviskol.RTM. from BASF. Particular examples are Luviskol VA 37 HM,
Luviskol VA 37 E and Luviskol VA 28. If the macromer backbones are
polyvinyl acetates, Mowilith 30 from Hoechst is particularly
suitable.
Polyvinyl alcohols that can be derivatized as described herein
preferably have a molecular weight of at least about 2,000. As an
upper limit, the PVA may have a molecular weight of up to
1,000,000. Preferably, the PVA has a molecular weight of up to
300,000, especially up to approximately 130,000, and especially
preferably up to approximately 60,000.
The PVA usually has a poly(2-hydroxy)ethylene structure. The PVA
derivatized in accordance with the disclosure may, however, also
comprise hydroxy groups in the form of 1,2-glycols.
The PVA system can be a fully hydrolyzed PVA, with all repeating
groups being --CH.sub.2--CH(OH), or a partially hydrolyzed PVA with
varying proportions (1% to 25%) of pendant ester groups. PVA with
pendant ester groups have repeating groups of the structure
CH.sub.2--CH(OR) where R is COCH.sub.3 group or longer alkyls, as
long as the water solubility of the PVA is preserved. The ester
groups can also be substituted by acetaldehyde or butyraldehyde
acetals that impart a certain degree of hydrophobicity and strength
to the PVA. For an application that requires an oxidatively stable
PVA, the commercially available PVA can be broken down by
NaIO.sub.4--KMnO.sub.4 oxidation to yield a small molecular weight
(2000 to 4000) PVA.
The PVA is prepared by basic or acidic, partial or virtually
complete hydrolysis of polyvinyl acetate. In a preferred
embodiment, the PVA comprises less than 50% of vinyl acetate units,
especially less than about 25% of vinyl acetate units. Preferred
amounts of residual acetate units in the PVA, based on the sum of
vinyl alcohol units and acetate units, are approximately from 3 to
25%.
Crosslinkable Groups
The macromers have at least two pendant chains containing groups
that can be crosslinked. The term group includes single
polymerizable moieties, such as an acrylate, as well as larger
crosslinkable regions, such as oligomeric or polymeric regions. The
crosslinkers are desirably present in an amount of from
approximately 0.01 to 10 milliequivalents of crosslinker per gram
of backbone (meq/g), more desirably about 0.05 to 1.5 meq/g. The
macromers can contain more than one type of crosslinkable
group.
The pendant chains are attached via the hydroxyl groups of the
polymer backbone. Desirably, the pendant chains having
crosslinkable groups are attached via cyclic acetal linkages to the
1,2-diol or 1,3-diol hydroxyl groups.
Crosslinking of the macromers may be via any of a number of means,
such as physical crosslinking or chemical crosslinking. Physical
crosslinking includes, but is not limited to, complexation,
hydrogen bonding, desolvation, Van der wals interactions, and ionic
bonding. Chemical crosslinking can be accomplished by a number of
means including, but not limited to, chain reaction (addition)
polymerization, step reaction (condensation) polymerization and
other methods of increasing the molecular weight of
polymers/oligomers to very high molecular weights. Chain reaction
polymerization includes, but is not limited to, free radical
polymerization (thermal, photo, redox, atom transfer
polymerization, etc.), cationic polymerization (including onium),
anionic polymerization (including group transfer polymerization),
certain types of coordination polymerization, certain types of ring
opening and metathesis polymerizations, etc. Step reaction
polymerizations include all polymerizations which follow step
growth kinetics including but not limited to reactions of
nucleophiles with electrophiles, certain types of coordination
polymerization, certain types of ring opening and metathesis
polymerizations, etc. Other methods of increasing molecular weight
of polymers/oligomers include but are not limited to
polyelectrolyte formation, grafting, ionic crosslinking, etc.
Various crosslinkable groups are known to those skilled in the art
and can be used, according to what type of crosslinking is desired.
For example, hydrogels can be formed by the ionic interaction of
divalent cationic metal ions (such as Ca.sup.+2 and Mg.sup.+2) with
ionic polysaccharides such as alginates, xanthan gums, natural gum,
agar, agarose, carrageenan, fucoidan, furcellaran, laminaran,
hypnea, eucheuma, gum arabic, gum ghatti, gum karaya, gum
tragacanth, locust beam gum, arabinogalactan, pectin, and
amylopectin. Multifunctional cationic polymers, such as
poly(l-lysine), poly(allylamine), poly (ethyleneimine),
poly(guanidine), poly(vinyl amine), which contain a plurality of
amine functionalities along the backbone, may be used to further
induce ionic crosslinks.
Hydrophobic interactions are often able to induce physical
entanglement, especially in polymers, that induces increases in
viscosity, precipitation, or gelation of polymeric solutions. Block
and graft copolymers of water soluble and insoluble polymers
exhibit such effects, for example,
poly(oxyethylene)-poly(oxypropylene) block copolymers, copolymers
of poly(oxyethylene) with poly(styrene), poly(caprolactone),
poly(butadiene), etc.
Solutions of other synthetic polymers such as
poly(N-alkylacrylamides) also form hydrogels that exhibit
thermoreversible behavior and exhibit weak physical crosslinks on
warming. A two component aqueous solution system may be selected so
that the first component (among other components) consists of
poly(acrylic acid) or poly(methacrylic acid) at an elevated pH of
around 8-9 and the other component consists of (among other
components) a solution of poly (ethylene glycol) at an acidic pH,
such that the two solutions on being combined in situ result in an
immediate increase in viscosity due to physical crosslinking.
Other means for polymerization of the macromers also may be
advantageously used with macromers that contain groups that
demonstrate activity towards functional groups such as amines,
imines, thiols, carboxyls, isocyanates, urethanes, amides,
thiocyanates, hydroxyls, etc., which may be naturally present in,
on, or around tissue. Alternatively, such functional groups
optionally may be provided in some of the macromers of the
composition. In this case, no external initiators of polymerization
are needed and polymerization proceeds spontaneously when two
complementary reactive functional groups containing moieties
interact at the application site.
Desirable crosslinkable groups include (meth)acrylamide,
(meth)acrylate, styryl, vinyl ester, vinyl ketone, vinyl ethers,
etc. Particularly desirable are ethylenically unsaturated
functional groups.
Ethylenically unsaturated groups can be crosslinked via free
radical initiated polymerization, including via photoinitiation,
redox initiation, and thermal initiation. Systems employing these
means of initiation are well known to those skilled in the art. In
one embodiment, a two part redox system is employed. One part of
the system contains a reducing agent such as a ferrous salt.
Various ferrous salts can be used, such as, for example, ferrous
gluconate dihydrate, ferrous lactate dihydrate, or ferrous acetate.
The other half of the solution contains an oxidizing agent such as
hydrogen peroxide. Either or both of the redox solutions can
contain macromer, or it may be in a third solution. The two
solutions are combined to initiate the crosslinking.
Other reducing agents can be used, such as, but not limited to,
cuprous salts, cerous salts, cobaltous salts, permanganate, and
manganous salts. Ascorbate, for example, can be used as a
coreductant to recycle the reductant and reduce the amount needed.
This can reduce the toxicity of a ferrous based system. Other
oxidizing agents that can be used include, but are not limited to,
t-butyl hydroperoxide, t-butyl peroxide, benzoyl peroxide, cumyl
peroxide, etc.
Specific Macromers
Specific macromers that are suitable for use in the embolic
compositions are disclosed in U.S. Pat. Nos. 5,508,317, 5,665,840,
5,807,927, 5,849,841, 5,932,674, 5,939,489, and 6,011,077.
In one embodiment, units containing a crosslinkable group conform,
in particular, to the formula I
##STR00001##
in which R is a linear or branched C.sub.1-C.sub.8 alkylene or a
linear or branched C.sub.1-C.sub.12 alkane. Suitable alkylene
examples include octylene, hexylene, pentylene, butylene,
propylene, ethylene, methylene, 2-propylene, 2-butylene and
3-pentylene. Preferably lower alkylene R has up to 6 and especially
preferably up to 4 carbon atoms. The groups ethylene and butylene
are especially preferred. Alkanes include, in particular, methane,
ethane, n- or isopropane, n-, sec- or tert-butane, n- or
isopentane, hexane, heptane, or octane. Preferred groups contain
one to four carbon atoms, in particular one carbon atom.
R.sub.1 is hydrogen, a C.sub.1-C.sub.6 alkyl, or a cycloalkyl, for
example, methyl, ethyl, propyl or butyl and R.sub.2 is hydrogen or
a C.sub.1-C.sub.6 alkyl, for example, methyl, ethyl, propyl or
butyl. R.sub.1 and R.sub.2 are preferably each hydrogen.
R.sub.3 is an olefinically unsaturated electron attracting
copolymerizable radical having up to 25 carbon atoms. In one
embodiment, R.sub.3 has the structure
##STR00002## where R.sub.4 is the
##STR00003## group if n=zero, or the
##STR00004## bridge if n=1;
R.sub.5 is hydrogen or C.sub.1-C.sub.4 alkyl, for example, n-butyl,
n- or isopropyl, ethyl, or methyl;
n is zero or 1, preferably zero; and
R.sub.6 and R.sub.7, independently of one another, are hydrogen, a
linear or branched C.sub.1-C.sub.8 alkyl, aryl or cyclohexyl, for
example one of the following: octyl, hexyl, pentyl, butyl, propyl,
ethyl, methyl, 2-propyl, 2-butyl or 3-pentyl. R.sub.6 is preferably
hydrogen or the CH.sub.3 group, and R.sub.7 is preferably a
C.sub.1-C.sub.4 alkyl group. R.sub.6 and R.sub.7 as aryl are
preferably phenyl.
In another embodiment, R.sub.3 is an olefinically unsaturated acyl
group of formula R.sub.8--CO--, in which R.sub.8 is an olefinically
unsaturated copolymerizable group having from 2 to 24 carbon atoms,
preferably from 2 to 8 carbon atoms, especially preferably from 2
to 4 carbon atoms. The olefinically unsaturated copolymerizable
radical R.sub.8 having from 2 to 24 carbon atoms is preferably
alkenyl having from 2 to 24 carbon atoms, especially alkenyl having
from 2 to 8 carbon atoms and especially preferably alkenyl having
from 2 to 4 carbon atoms, for example ethenyl, 2-propenyl, 3
-propenyl, 2-butenyl, hexenyl, octenyl or dodecenyl. The groups
ethenyl and 2-propenyl are preferred, so that the group
--CO--R.sub.8 is the acyl radical of acrylic or methacrylic
acid.
In another embodiment, the group R.sub.3 is a radical of formula
--[CO--NH--(R.sub.9--NH--CO--O).sub.q--R.sub.10--O].sub.p--CO--R.sub.8
wherein p and q are zero or one and
R.sub.9 and R.sub.10 are each independently lower alkylene having
from 2 to 8 carbon atoms, arylene having from 6 to 12 carbon atoms,
a saturated divalent cycloaliphatic group having from 6 to 10
carbon atoms, arylenealkylene or alkylenearylene having from 7 to
14 carbon atoms or arylenealkylenearylene having from 13 to 16
carbon atoms, and
R.sub.8 is as defined above.
Lower alkylene R.sub.9or R.sub.10 preferably has from 2 to 6 carbon
atoms and is especially straight-chained. Suitable examples include
propylene, butylene, hexylene, dimethylethylene and, especially
preferably, ethylene.
Arylene R.sub.9 or R.sub.10 is preferably phenylene that is
unsubstituted or is substituted by lower alkyl or lower alkoxy,
especially 1,3-phenylene or 1,4-phenylene or
methyl-1,4-phenylene.
A saturated divalent cycloaliphatic group R.sub.9 or R.sub.10 is
preferably cyclohexylene or cyclohexylene-lower alkylene, for
example cyclohexylenemethylene, that is unsubstituted or is
substituted by one or more methyl groups, such as, for example,
trimethylcyclohexylenemethylene, for example the divalent
isophorone radical.
The arylene unit of alkylenearylene or arylenealkylene R.sub.9 or
R.sub.10 is preferably phenylene, unsubstituted or substituted by
lower alkyl or lower alkoxy, and the alkylene unit thereof is
preferably lower alkylene, such as methylene or ethylene,
especially methylene. Such radicals R.sub.9 or R.sub.10 are
therefore preferably phenylenemethylene or methylenephenylene.
Arylenealkylenearylene R.sub.9 or R.sub.10 is preferably
phenylene-lower alkylene-phenylene having up to 4 carbon atoms in
the alkylene unit, for example phenyleneethylenephenylene.
The groups R.sub.9 and R.sub.10 are each independently preferably
lower alkylene having from 2 to 6 carbon atoms, phenylene,
unsubstituted or substituted by lower alkyl, cyclohexylene or
cyclohexylene-lower alkylene, unsubstituted or substituted by lower
alkyl, phenylene-lower alkylene, lower alkylenephenylene or
phenylene-lower alkylene-phenylene.
The group --R.sub.9--NH--CO--O-- is present when q is one and
absent when q is zero. Macromers in which q is zero are
preferred.
The group --CO--NH--(R.sub.9--NH--CO--O).sub.q--R.sub.10--O-- is
present when p is one and absent when p is zero. Macromers in which
p is zero are preferred.
In macromers in which p is one, q is preferably zero. Macromers in
which p is one, q is zero, and R.sub.10 is lower alkylene are
especially preferred.
All of the above groups can be monosubstituted or polysubstituted,
examples of suitable substituents being the following:
C.sub.1-C.sub.4 alkyl, such as methyl, ethyl or propyl, --COOH,
--OH, --SH, C.sub.1-C.sub.4 alkoxy (such as methoxy, ethoxy,
propoxy, butoxy, or isobutoxy), --NO.sub.2, --NH.sub.2,
--NH(C.sub.1-C.sub.4), --NH--CO--NH.sub.2, --N(C.sub.1-C.sub.4
alkyl).sub.2, phenyl (unsubstituted or substituted by, for example,
--OH or halogen, such as Cl, Br or especially I),
--S(C.sub.1-C.sub.4 alkyl), a 5- or 6-membered heterocyclic ring,
such as, in particular, indole or imidazole, --NH--C(NH)--NH.sub.2,
phenoxyphenyl (unsubstituted or substituted by, for example, --OH
or halogen, such as Cl, Br or especially I), an olefinic group,
such as ethylene or vinyl, and CO--NH--C(NH)--NH.sub.2.
Preferred substituents are lower alkyl, which here, as elsewhere in
this description, is preferably C.sub.1-C.sub.4 alkyl,
C.sub.1-C.sub.4 alkoxy, COOH, SH, --NH.sub.2, --NH(C.sub.1-C.sub.4
alkyl), --N(C.sub.1-C.sub.4 alkyl).sub.2 or halogen. Particular
preference is given to C.sub.1-C.sub.4 alkyl, C.sub.1-C.sub.4
alkoxy, COOH and SH.
For the purposes of this invention, cycloalkyl is, in particular,
cycloalkyl, and aryl is, in particular, phenyl, unsubstituted or
substituted as described above.
Modifiers
The macromers can include further modifier groups and crosslinkable
groups. Some such groups are described in U.S. Pat. Nos. 5,508,317,
5,665,840, 5,807,927, 5,849,841, 5,932,674, 5,939,489, and
6,011,077. Crosslinkable groups and the optional further modifier
groups can be bonded to the macromer backbone in various ways, for
example through a certain percentage of the 1,3-diol units being
modified to give a 1,3-dioxane, which contains a crosslinkable
group, or a further modifier, in the 2-position. Modifiers that
might be attached to the backbone include those to modify the
hydrophobicity, active agents or groups to allow attachment of
active agents, photoinitiators, modifiers to enhance or reduce
adhesiveness, modifiers to impart thermoresponsiveness, modifiers
to impart other types of responsiveness, and additional
crosslinking groups. These modifiers may be attached to the
hydroxyl groups in the backbone, or to other monomeric units
included in the backbone.
Attaching a cellular adhesion promoter to the macromers can enhance
cellular attachment or adhesiveness of the embolic agents formed by
the embolic compositions. These agents are well known to those
skilled in the art and include carboxymethyl dextran,
proteoglycans, collagen, gelatin, glucosaminoglycans, fibronectin,
lectins, polycations, and natural or synthetic biological cell
adhesion agents such as RGD peptides.
Having pendant ester groups that are substituted by acetaldehyde or
butyraldehyde acetals, for example, can increase the hydrophobicity
of the macromers and the formed hydrogel. Hydrophobic groups can
desirably be present in an amount from about 0 to 25%.
It may also be desirable to include on the macromer a molecule that
allows visualization of the formed hydrogel. Examples include dyes
and molecules visualizable by magnetic resonance imaging.
Degradable Regions
The macromers can form a hydrogel that is degradable. Suitable
degradable systems are described in U.S. patent application Ser.
No. 09/714,700, titled "Degradable Poly(Vinyl Alcohol) Hydrogels"
and filed on Nov. 15, 2000. In the degradable systems described in
that application, the macromers include a degradable region in the
backbone or on a pendant chain. The degradable region is preferably
degradable under in vivo conditions by hydrolysis. The degradable
region can be enzymatically degradable. For example, the degradable
region may be polymers and oligomers of glycolide, lactide,
-caprolactone, other hydroxy acids, and other biologically
degradable polymers that yield materials that are non-toxic or
present as normal metabolites in the body. Preferred
poly(.alpha.-hydroxy acids) are poly(glycolic acid), poly
(DL-lactic acid) and poly(L-lactic acid). Other useful materials
include poly(amino acids), poly(anhydrides), poly (orthoesters),
poly(phosphazines), and poly(phosphoesters). Polylactones such as
poly( -caprolactone), poly( -caprolactone),
poly(.delta.-valerolactone) and poly(.gamma.-butyrolactone), for
example, are also useful. Enzymatically degradable linkages include
poly(amino acids), gelatin, chitosan, and carbohydrates. The
biodegradable regions may have a degree of polymerization ranging
from one up to values that would yield a product that was not
substantially water soluble. Thus, monomeric, dimeric, trimeric,
oligomeric, and polymeric regions may be used. The biodegradable
region could, for example, be a single methacrylate group.
Biodegradable regions can be constructed from polymers or monomers
using linkages susceptible to biodegradation, such as ester,
acetal, carbonate, peptide, anhydride, orthoester, phosphazine, and
phosphoester bonds. The biodegradable regions may be arranged
within the macromers such that the formed hydrogel has a range of
degradability, both in terms of extent of degradation, whether
complete or partial, and in terms of time to complete or partial
degradation.
Synthesis of Macromers
The macromers can be made by general synthetic methods known to
those skilled in the art. The specific macromers discussed above
can be made as described in U.S. Pat. Nos. 5,508,317, 5,665,840,
5,807,927, 5,849,841, 5,932,674, 5,939,489, and 6,011,077.
The specific macromers described above are extraordinarily stable.
Spontaneous crosslinking by homopolymerization does not typically
occur. The macromers can furthermore be purified in a manner known
per se, for example by precipitation with organic solvents, such as
acetone, extraction in a suitable solvent, washing, dialysis,
filtration, or ultrafiltration. Ultrafiltration is especially
preferred. By means of the purification process the macromers can
be obtained in extremely pure form, for example in the form of
concentrated aqueous solutions that are free, or at least
substantially free, from reaction products, such as salts, and from
starting materials.
The preferred purification process for the macromers of the
invention, ultrafiltration, can be carried out in a manner known
per se. It is possible for the ultrafiltration to be carried out
repeatedly, for example from two to ten times. Alternatively, the
ultrafiltration can be carried out continuously until the selected
degree of purity is attained. The selected degree of purity can in
principle be as high as desired. A suitable measure for the degree
of purity is, for example, the sodium chloride content of the
solution, which can be determined simply in a known manner, such as
by conductivity measurements.
The macromers are crosslinkable in an extremely effective and
controlled manner.
Vinylic Comonomers
The process for polymerization of the macromers may comprise, for
example, crosslinking a macromer comprising units of formula I,
especially in substantially pure form, that is to say, for example,
after single or repeated ultrafiltration, preferably in solution,
especially in aqueous solution, in the absence or presence of an
additional vinylic comonomer.
The vinylic comonomer may be hydrophilic or hydrophobic, or a
mixture of a hydrophobic and a hydrophilic vinylic monomer.
Generally, approximately from 0.01 to 80 units of a typical vinylic
comonomer react per unit of formula I, especially from 1 to 30
units per unit of formula I, and especially preferably from 5 to 20
units per unit of formula I.
It is also preferable to use a hydrophobic vinylic comonomer or a
mixture of a hydrophobic vinylic comonomer with a hydrophilic
vinylic comonomer, the mixture comprising at least 50 percent by
weight of a hydrophobic vinylic comonomer. In that manner the
mechanical properties of the polymer can be improved without the
water content falling substantially. In principle, however, both
conventional hydrophobic vinylic comonomers and conventional
hydrophilic vinylic comonomers are suitable for copolymerization
with the macromer.
Suitable hydrophobic vinylic comonomers include, without the list
being exhaustive, C.sub.1-C.sub.18 alkyl acrylates and
methacrylates, C.sub.3-C.sub.18 alkyl acrylamides and
methacrylamides, acrylonitrile, methacrylonitrile,
vinyl-C.sub.1-C.sub.18 alkanoates, C.sub.2-C.sub.18 alkenes,
C.sub.2-C.sub.18 haloalkenes, styrene, C.sub.1-C.sub.6
alkylstyrene, vinyl alkyl ethers, in which the alkyl moiety
contains from 1 to 6 carbon atoms, C.sub.2-C.sub.10 perfluoroalkyl
acrylates and methacrylates or correspondingly partially
fluorinated acrylates and methacrylates, C.sub.3-C.sub.12
perfluoroalkyl-ethylthiocarbonylaminoethyl acrylates and
methacrylates, acryloxy- and methacryloxy-alkylsiloxanes,
N-vinylcarbazole, C.sub.3-C.sub.12 alkyl-esters of maleic acid,
fumaric acid, itaconic acid, mesaconic acid and the like.
C.sub.1-C.sub.4 alkyl esters of vinylically unsaturated carboxylic
acids having from 3 to 5 carbon atoms or vinyl esters of carboxylic
acids having up to 5 carbon atoms, for example, are preferred.
Examples of suitable hydrophobic vinylic comonomers include methyl
acrylate, ethyl acrylate, propyl acrylate, isopropyl acrylate,
cyclohexyl acrylate, 2-ethylhexyl acrylate, methyl methacrylate,
ethyl methacrylate, propyl methacrylate, vinyl acetate, vinyl
propionate, vinyl butyrate, vinyl valerate, styrene, chloroprene,
vinyl chloride, vinylidene chloride, acrylonitrile, 1-butene,
butadiene, methacrylonitrile, vinyltoluene, vinyl ethyl ether,
perfluorohexylethylthiocarbonylaminoethyl methacrylate, isobornyl
methacrylate, trifluoroethyl methacrylate, hexafluoroisopropyl
methacrylate, hexafluorobutyl methacrylate,
tris-trimethylsilyloxy-silyl-propyl methacrylate,
3-methacryloxypropylpentamethyldisiloxane and
bis(methacryloxypropyl) tetramethyldisiloxane.
Suitable hydrophilic vinylic comonomers include, without the list
being exhaustive, hydroxy-substituted lower alkyl acrylates and
methacrylates, acrylamide, methacrylamide, lower alkyl acrylamides
and methacrylamides, ethoxylated acrylates and methacrylates,
hydroxy-substituted lower alkyl acrylamides and methacrylamides,
hydroxy-substituted lower alkyl vinyl ethers, sodium
ethylenesulfonate, sodium styrenesulfonate,
2-acrylamido-2-methylpropanesulfonic acid (AMPS.RTM. monomer from
Lubrizol Corporation), N-vinylpyrrole, N-vinylsuccinimide,
N-vinylpyrrolidone, 2- or 4 -vinylpyridine, acrylic acid,
methacrylic acid, amino- (the term "amino" also including
quaternary ammonium), mono-lower alkylamino- or di-lower
alkylamino-lower alkyl acrylates and methacrylates, allyl alcohol
and the like. Hydroxy-substituted C.sub.2-C.sub.4
alkyl(meth)acrylates, five- to seven-membered N-vinyl lactams,
N,N-di-C.sub.1-C.sub.4 alkyl(meth) acrylamides and vinylically
unsaturated carboxylic acids having a total of from 3 to 5 carbon
atoms, for example, are preferred.
Contrast Agents
It may be desirable to include a contrast agent in the embolic
compositions. A contrast agent is a biocompatible (non-toxic)
material capable of being monitored by, for example, radiography.
The contrast agent can be water soluble or water insoluble.
Examples of water soluble contrast agents include metrizamide,
iopamidol, iothalamate sodium, iodomide sodium, and meglumine.
Iodinated liquid contrast agents include Omnipaque.RTM.,
Visipaque.RTM., and Hypaque-76.RTM.. Examples of water insoluble
contrast agents are tantalum, tantalum oxide, barium sulfate, gold,
tungsten, and platinum. These are commonly available as particles
preferably having a size of about 10 .mu.m or less.
The contrast agent can be added to the embolic compositions prior
to administration. Both solid and liquid contrast agents can be
simply mixed with a solution of the liquid embolic compositions or
with the solid articles. Liquid contrast agent can be mixed at a
concentration of about 10 to 80 volume percent, more desirably
about 20 to 50 volume percent. Solid contrast agents are desirably
added in an amount of about 10 to 40 weight percent, more
preferably about 20 to 40 weight percent.
Occlusive Devices
It may be desirable to use the embolic compositions in combination
with one or more occlusive devices. Such devices include balloons,
microcoils, and other devices known to those skilled in the art.
The device can be placed at the site to be occluded or filled
before, during, or after the embolic composition is administered.
For example, an occlusive coil can be placed in an aneurysm sac to
be filled and the liquid embolic composition can be injected into
the sac to fill the space around the coil. An advantage of using an
occlusive device along with the embolic composition is that it may
provide greater rigidity to the filling.
Active Agents
An effective amount of one or more biologically active agents can
be included in the embolic compositions. It may be desirable to
deliver the active agent from the formed hydrogel. Biologically
active agents that it may be desirable to deliver include
prophylactic, therapeutic, and diagnostic agents including organic
and inorganic molecules and cells (collectively referred to herein
as an "active agent" or "drug"). A wide variety of active agents
can be incorporated into the hydrogel. Release of the incorporated
additive from the hydrogel is achieved by diffusion of the agent
from the hydrogel, degradation of the hydrogel, and/or degradation
of a chemical link coupling the agent to the polymer. In this
context, an "effective amount" refers to the amount of active agent
required to obtain the desired effect.
Examples of active agents that can be incorporated include, but are
not limited to, anti-angiogenic agents, chemotherapeutic agents,
radiation delivery devices, such as radioactive seeds for
brachytherapy, and gene therapy compositions.
Chemotherapeutic agents that can be incorporated include water
soluble chemotherapeutic agents, such as cisplatin (platinol),
doxorubicin (adriamycin, rubex), or mitomycin C (mutamycin). Other
chemotherapeutic agents include iodinated fatty acid ethyl esters
of poppy seed oil, such as lipiodol.
Cells can be incorporated into the embolic compositions, including
cells to encourage tissue growth or cells to secrete a desired
active agent. For example, cells that can be incorporated include
fibroblasts, endothelial cells, muscle cells, stem cells, etc.
Cells can be modified to secrete active agents such as growth
factors.
Active agents can be incorporated into the liquid embolic
compositions simply by mixing the agent with the embolic
composition prior to administration. The active agent will then be
entrapped in the hydrogel that is formed upon administration of the
embolic composition. Active agents can be incorporated into the
preformed embolic articles through encapsulation and other methods
known in the art and discussed further below. The active agent can
be in compound form or can be in the form of degradable or
nondegradable nano or microspheres. It some cases, it may be
possible and desirable to attach the active agent to the macromer
or to the preformed article. The active agent may also be coated
onto the surface of the preformed article. The active agent may be
released from the macromer or hydrogel over time or in response to
an environmental condition.
Other Additives
It may be desirable to include a peroxide stabilizer in redox
initiated systems. Examples of peroxide stabilizers are
Dequest.RTM. products from Solutia Inc., such as for example
Dequest.RTM. 2010 and Dequest.RTM. 2060S. These are phosphonates
and chelants that offer stabilization of peroxide systems.
Dequest.RTM. 2060S is diethylenetriamine penta(methylene phosphonic
acid). These can be added in amounts as recommended by the
manufacturer.
It may be desirable to include fillers in the embolic compositions,
such as fillers that leach out of the formed hydrogel over a period
of time and cause the hydrogel to become porous. Such may be
desirable, for example, where the embolic composition is used for
chemoembolization and it may be desirable to administer a follow up
dose of chemoactive agent. Appropriate fillers include calcium
salts, for example.
Characteristics that can be Modified
The embolic compositions are highly versatile. A number of
characteristics can be easily modified, making the embolic
compositions suitable for a number of applications. For example, as
discussed above, the polymer backbones can include comonomers to
add desired properties, such as, for example, thermoresponsiveness,
degradability, gelation speed, and hydrophobicity. Modifiers can be
attached to the polymer backbone (or to pendant groups) to add
desired properties, such as, for example, thermoresponsiveness,
degradability, hydrophobicity, and adhesiveness. Active agents can
also be attached to the polymer backbone using the free hydroxyl
groups, or can be attached to pendant groups.
The gelation time of the liquid embolic compositions can be varied
from about 0.5 seconds to as long as 10 minutes, and longer if
desired. However, the preferred gelation time for most liquid
embolic applications will be less than about 5 seconds, desirably
less than about 2 seconds. The desired gelation time will depend
upon whether it is desired to form a plug near the catheter tip or
to form a more diffuse network. A longer gelation time will
generally be required if crosslinking is initiated a distance from
the intended embolic site.
The gelation time will generally be affected by, and can be
modified by changing at least the following variables: the
initiator system, crosslinker density, macromer molecular weight,
macromer concentration (solids content), and type of crosslinker. A
higher crosslinker density will provide faster gelation time; a
lower molecular weight will provide a slower gelation time. A
higher solids content will provide faster gelation time. For redox
systems the gelation time can be designed by varying the
concentrations of the redox components. Higher reductant and higher
oxidant will provide faster gelation, higher buffer concentration
and lower pH will provide faster gelation.
The firmness of the formed hydrogel will be determined in part by
the hydrophilic/hydrophobic balance, where a higher hydrophobic
percent provides a firmer hydrogel. The firmness will also be
determined by the crosslinker density (higher density provides a
firmer hydrogel), the macromer molecular weight (lower MW provides
a firmer hydrogel), and the length of the crosslinker (a shorter
crosslinker provides a firmer hydrogel).
The swelling of the hydrogel is inversely proportional to the
crosslinker density. Generally, no or minimal swelling is desired,
desirably less than about 10 percent.
Elasticity of the formed hydrogel can be increased by increasing
the size of the backbone between crosslinks and decreasing the
crosslinker density. Incomplete crosslinking will also provide a
more elastic hydrogel. Preferably the elasticity of the hydrogel
substantially matches the elasticity of the tissue to which the
embolic composition is to administered.
Making Preformed Embolic Articles
Preformed articles are made, in general, by dissolving macromers in
an appropriate solvent, shaping the macromers such as by pouring
the macromer solution in a mold, if desired, and crosslinking the
macromers. A mold is suitable for use in making rod shaped
articles, for example. Microparticles can be made by forming a
hydrogel sheet and milling it into particles. Such particles will
be irregular in size and shape.
In one embodiment, the preformed articles are spherical
microparticles termed microspheres. Microparticles can be made by a
number of techniques known to those skilled in the art, such as
single and double emulsion, suspension polymerization, solvent
evaporation, spray drying, and solvent extraction. Methods for
making microspheres are described in the literature, for example,
in Mathiowitz and Langer, J. Controlled Release 5:13-22 (1987);
Mathiowitz et al., Reactive Polymers 6:275-283 (1987); Mathiowitz
et al., J. Appl. Polymer Sci. 35:755-774 (1988); Mathiowitz et al.,
Scanning Microscopy 4:329-340 (1990); Mathiowitz et al., J. Appl.
Polymer Sci., 45:125-134 (1992); and Benita et al., J. Pharm. Sci.
73:1721-1724 (1984).
In solvent evaporation, described for example in Mathiowitz et al.,
(1990), Benita et al. (1984), and U.S. Pat. No. 4,272,398, the
macromers are dissolved in a solvent. If desired, an agent to be
incorporated, either in soluble form or dispersed as fine
particles, is added to the macromer solution, and the mixture is
suspended in an aqueous phase that contains a surface active agent.
The resulting emulsion is stirred until most of the solvent
evaporates, leaving solid microspheres, which may be washed with
water and dried overnight in a lyophilizer. The microspheres are
polymerized, for example, by exposure to light.
In solvent removal, the macromers are dissolved in a solvent. The
mixture can then be suspended in oil, such as silicon oil, by
stirring, to form an emulsion. As the solvent diffuses into the oil
phase, the emulsion droplets harden into solid polymer
microspheres. The microspheres can be polymerized by exposure to
light, for example.
Spray drying is implemented by passing the polymerizable macromers
used to form the hydrogel through a nozzle, spinning disk or
equivalent device to atomize the mixture to form fine droplets. The
polymerizable macromers may be provided in a solution or
suspension, such as an aqueous solution. The fine droplets are
exposed to light, for example, to cause polymerization of the
macromer and formation of the hydrogel microspheres.
In another embodiment, hydrogel particles are prepared by a
water-in-oil emulsion or suspension process, wherein the
polymerizable macromers and the substance to be incorporated, if
desired, are suspended in a water-in-oil suspension and exposed to
light to polymerize the macromers to form hydrogel particles
incorporating the substance, such as a biologically active
agent.
In another embodiment, microspheres can be formed by atomizing
macromer solution into oil, followed by polymerization.
There are many variables that affect the size, size distribution,
and quality of the microspheres formed. An important variable is
the choice of stabilizer. Good stabilizers have an HLB number from
1 to 4 and have some solubility in the oil phase. Some appropriate
stabilizers include cellulose acetate butyrate (with 17% butyrate),
sorbitan oleates, and dioctylsulphosuccinate. The amount and type
of stabilizer will control the particle size and reduce coalescing
of the particles during crosslinking. The oil can be a
water-insoluble oil such as liquid paraffin, but water-insoluble
halogenated solvents such as dichloroethane are commonly used. The
ratio of water to oil is also important and desirably ranges from
about 1:1 to 1:4.
Microspheres can be made in sizes ranging from about 10 microns to
2000 microns. In most applications it will be desirable to have a
small size range of microspheres. The process used to make the
microspheres can be controlled to achieve a particular desired size
range of microspheres. Other methods, such as sieving, can be used
to even more tightly control the size range of the
microspheres.
Active agents can be included in the microspheres as described
above. It may be desirable to coat the microspheres in modifiers or
active agents, such as, for example, agents to increase cellular
attachment. Such coating can be done by methods known to those
skilled in the art.
II. Methods of Using the Embolic Compositions
The embolic compositions can be used for a variety of applications
such as, but nut limited to, vascular occlusion for treatment of
tumors or fibroids, occlusion of vascular malformations, such as
arteriovenous malformations (AVM), occlusion of the left atrial
appendage, fillers for aneurysm sacs, endoleak sealants, arterial
sealants, puncture sealants, and occlusion of other lumens such as
fallopian tubes.
According to the general method, an effective amount of the embolic
composition in an aqueous solvent is administered into a lumen or
void. In one embodiment, the macromers are crosslinked in situ. The
term "effective amount", as used herein, means the quantity of
embolic composition needed to fill or block the biological
structure of interest. The effective amount of embolic composition
administered to a particular patient will vary depending upon a
number of factors, including the sex, weight, age, and general
health of the patient, the type, concentration, and consistency of
the macromers and the hydrogel that results from crosslinking, and
the particular site and condition being treated. The macromers may
be administered over a number of treatment sessions.
The methods of using the liquid embolic compositions involve
combining the components, including any comonomers and other
additives, under conditions suitable for crosslinking of the
macromers. The crosslinking is suitably carried out in a solvent. A
suitable solvent is in principle any solvent that dissolves the
macromers, for example water, alcohols, such as lower alkanols, for
example ethanol or methanol, also carboxylic acid amides, such as
dimethylformamide, or dimethyl sulfoxide, and also a mixture of
suitable solvents, such as, for example, a mixture of water with an
alcohol, such as, for example, a water/ethanol or a water/methanol
mixture. The combination of the macromers is preferably carried out
in a substantially aqueous solution. In accordance with the
invention, the criterion that the macromer is soluble in water
denotes in particular that the macromer is soluble in a
concentration of approximately from 3 to 90 percent by weight,
preferably approximately from 5 to 60 percent by weight, in a
substantially aqueous solution. Insofar as it is possible in an
individual case, macromer concentrations of more than 90 percent
are also included in accordance with the invention.
Within the scope of this invention, substantially aqueous solutions
of the macromer comprise especially solutions of the macromer in
water, in aqueous salt solutions, especially in aqueous solutions
that have an osmolarity of approximately from 200 to 450 milliosmol
per 1000 ml (mOsm/l), preferably an osmolarity of approximately
from 250 to 350 mOsm/l, especially approximately 300 mOsm/l, or in
mixtures of waterer aqueous salt solutions with physiologically
tolerable polar organic solvents, such as, for example, glycerol.
Solutions of the macromer in water or in aqueous salt solutions are
preferred.
The viscosity of the solution of the macromer in the substantially
aqueous solution is, within wide limits, not critical, but the
solution should preferably be a flowable solution that can be
delivered through an appropriately sized catheter or syringe. For
delivery through microcatheters, viscosities in the range of about
10 to 50 cp are desirable. The viscosity can be substantially
higher for delivery through a syringe. The viscosity will generally
be controlled by the molecular weight of the macromers, the solids
content of the solution, and the type and amount of contrast agent
present.
The solids content of the solution will preferably range from about
2 percent by weight to about 30 percent by weight, desirably from
about 6 to 12 percent by weight.
In one embodiment, the macromers are crosslinkable via free radical
polymerization. In one embodiment, the crosslinking initiator is
mixed with the macromer solution before administration, during
administration, or after administration. For example, a redox
system can be mixed with the macromer solution at the time of
administration. In one embodiment, the crosslinking initiator may
be present at the site of administration. For example, the
initiator could be a substance, such as charged blood components,
present at the site. Macromers can be used that crosslink when they
contact each other. These can be mixed before, during, or after
administration. In one embodiment, the crosslinking initiator is an
applied stimulus, such as light or heat, which causes crosslinking.
Suitable initiators are known for thermal, photo, and redox
initiated polymerization. In a redox initiated system employing
ferrous ion, peroxide, and ascorbate, the desired amounts of the
components will be determined by concerns related to gelation
speed, toxicity, extent of gelation desired, and stability. Very
generally, the concentration of iron will be about 20 to 1000 ppm;
the concentration of hydrogen peroxide will be about 10 to 1000
ppm; the pH will be about 3 to 7; the buffer concentration will be
about 10 to 200 mM; and ascorbate concentration will be about 10 to
40 mM.
It may be desirable, if initiator is added before administration,
to use a system that provides delayed crosslinking so that the
embolic composition does not gel too early. Moreover, using delayed
curing, the composition can assume or be formed into a desired
shape before complete curing has occurred.
In some embodiments, the embolic composition should be injected
before substantial crosslinking of the macromers has occurred. This
allows the macromers to continue crosslinking in situ and prevents
blockage of the syringe needle or catheter with gelled polymer. In
addition, such in situ crosslinking may allow anchoring of the
hydrogel to host tissue by covalently bonding with collagen
molecules present within the host tissue.
Since the embolic compositions preferably comprise no undesired
low-molecular-weight constituents, the crosslinked hydrogel
products also comprise no such constituents. The embolic agents
obtainable by the embolic compositions are therefore distinguished,
in an advantageous embodiment, by the fact that they are extremely
clean.
The embolic compositions can be used in combination with other
methods. For example, the embolic compositions can be used with
thermal or laser ablation, where the liquid embolic agent may be
placed initially, followed by thermal or laser ablation, to provide
a synergistic effect with enhanced efficacy.
The preformed embolic articles can be administered similarly to how
solid embolic agents are presently administered. The microspheres
will desirably be supplied in physiological, sterile saline. A
microcatheter, for example, can be used to deliver the microspheres
to the desired administration site. It may be desirable to mix a
contrast agent and/or chemotherapeutic agent with the microspheres
before administration.
Delivery Devices
The compositions can be delivered to the intended site of embolism
using delivery devices generally known to those skilled in the art.
In most cases, a catheter or syringe is used. In many cases, a
multi-lumen catheter is used to deliver the liquid embolic
composition to the intended site of administration. Generally, a
two or three lumen catheter will be used, wherein the components of
the composition which crosslink or initiate crosslinking are
maintained in separate lumens until the time of administration. For
example, in the case of a macromer that crosslinks via redox
initiated free radical polymerization, one solution containing the
reducing agent is delivered through a first lumen while a solution
containing the oxidizing agent is delivered through a second lumen.
The macromer can be in one or both of the solutions. A third lumen
can be used to deliver contrast agent or the contrast agent can be
in either or both of the redox solutions. A guidewire can be
inserted through any of the lumens, and removed prior to delivery
of a solution through that lumen.
In one embodiment, the catheter includes a mixing chamber at its
delivery tip. A side by side "double D" lumen can be used, wherein
the interior wall has been removed at the distal end to form an
area where the two solutions combine before they are injected into
the lumen or void. Alternatively, a coaxial catheter can be used,
where one of the inner or outer lumens extends further than the
other. Other types of multi-lumen catheters are disclosed in the
art.
Vascular Embolics
The embolic compositions can be used to form a plug in a variety of
biological lumens. For example, the compositions can be delivered
endovascularly to plug the feeder vessel(s) of a tumor or a uterine
fibroid. It may be desirable in some cases to use a slowly
crosslinking formulation as a liquid embolic composition so that
the embolic composition diffuses before gelation and a network or
web of polymerized hydrogel is formed. In other cases, where a more
compact embolization is desired close to the site of
administration, it is desirable to use a more quickly crosslinking
formulation.
In one embodiment, a redox initiated macromer composition is used.
Using a triple lumen catheter, a solution containing the reductant
is introduced through one lumen, a solution containing the oxidant
is introduced using a second lumen, and the third lumen is used for
introducing liquid contrast to monitor the site before and after
administration of the embolic composition. The macromer can be in
one or both of the reductant and oxidant solutions. Desirably, a
contrast agent is present in one or both of the reductant or
oxidant solutions so that administration of the embolic composition
can be monitored. The uterine artery, for example, to be embolized
can be accessed through the femoral artery or transcervically.
Filling Aneurysm Sacs
Many aneurysms, particularly cerebral aneurysms, can be treated
endovascularly by occluding the aneurysm with the embolic
composition. The embolic composition is administered using a
microcatheter. Methods of administering embolic agents are known to
those skilled in the art and generally can be used with the embolic
composition.
In one embodiment, a redox initiated macromer composition is used,
as described above for lumen embolics. It may be desirable to use a
balloon, a stent, or another mechanism, for temporarily isolating
the aneurysm and providing a template for embolic formation.
AAAs and TAAs are currently treated endovascularly by the placement
of a stent graft at the site of the aneurysm. Often, there are
leaks into the excluded aneurysm sac, termed endoleaks, due to
feeder vessels into the sac, spaces between the stent graft and the
vessel wall, or holes in the stent graft wall. Such endoleaks can
cause the aneurysm to further expand and to rupture. The embolic
compositions disclosed herein can be used to seal endoleaks. In one
embodiment, the embolic compositions are used to fill the aneurysm
sac.
An excluded aneurysm sac can be accessed in at least three ways:
using a catheter to access the sac through the stent graft side
wall; using a syringe to access the excluded sac through the
patient's back; or using a catheter to access the sac through blood
vessels feeding the sac. Any of theses methods can be used to
administer the embolic compositions into the sac. If the endoleak
is due to a feeder vessel, it may be desirable to endovascularly
access the sac through the feeder vessel. Using this method, the
sac can be filled and the vessel embolized, if desired. In some
cases, it may be difficult to endovascularly access the sac and it
may be preferable to inject embolic composition directly into the
sac using a syringe through the patient's back.
It may be desirable to use a more adhesive embolic composition,
which will adhere to the vessel wall within the aneurysm sac and
discourage leakage between the hydrogel mass and the vessel
wall.
Chemoembolization
The embolic compositions can be used for chemoembolization. As
described above, a chemotherapeutic agent is incorporated into the
embolic compositions or simply mixed with the preformed embolic
articles. The embolic composition is then administered as described
above.
For chemoembolization, as well as other applications, it may be
desirable to use an embolizing composition that forms a partially
or fully degradable hydrogel. Current practice calls for several
applications of chemotherapeutic agent at time intervals of about 4
to 8 weeks. The embolic compositions can be formulated to degrade,
partially or fully, over a desired period of time, at which time
the chemoembolic composition or just the chemotherapeutic agent can
be readministered. In another embodiment, embolectomy methods can
be used to recannulate the embolization to allow reapplication of
chemotherapeutic agent.
In another embodiment, the chemoembolic composition forms a
hydrogel that releases the chemotherapeutic agent over the entire
desired treatment period.
EXAMPLES
The examples below serve to further illustrate the invention, to
provide those of ordinary skill in the art with a complete
disclosure and description of how the compounds, compositions,
articles, devices, and/or methods claimed herein are made and
evaluated, and are not intended to limit the scope of the
invention. In the examples, unless expressly stated otherwise,
amounts and percentages are by weight, temperature is in degrees
Celsius or is at ambient temperature, and pressure is at or near
atmospheric. The examples are not intended to restrict the scope of
the invention.
Example 1
Embolization of Rabbit Renal Vasculature with Liquid Embolic
Compositions
General Procedure:
Following general anaesthesia, the superficial femoral artery was
surgically exposed and a microcatheter (three lumen, 3.4 Fr from
ACT Medical unless otherwise noted) was introduced using a
guidewire. One of the lumens was used to administer contrast agent
to the animal. The microcatheter was advanced under fluoroscopic
guidance to the left renal artery. The embolic composition was
injected under fluoroscopic control. Following polymer injection,
localization of the cured radio-opaque polymer was followed up by
conducting an angiogram to assess whether complete blockage of the
kidney vasculature was achieved.
The liquid embolic compositions were two part redox formulations
having reductant and oxidant solutions. The macromer for all
samples except F had a PVA backbone (14 kDa, 12% acetate
incorporation) modified with 0.45 meq/g N-acrylamidoacetaldehyde di
methyl acetal pendant polymerizable groups (about 6.3 crosslinks
per chain). In Sample F, the macromer had a PVA backbone (6 kDa,
80% hydrolyzed from Polysciences) modified with 1.0 meq/g
N-acrylamidoacetaldehyde dimethyl acetal and 0.5 meq/g acetaldehyde
dimethyl acetal (a hydrophobic modifier). The macromers were made
substantially as described in U.S. Pat. No. 5,932,674
The comonomer used was AMPS. The contrast agent was Omnipaque.RTM..
The buffer used in the oxidant solutions was 1M acetate buffer,
pH=4.1. None of the reductant solutions contained buffer.
TABLE-US-00001 TABLE 1 Composition Components A B C D E F G H I
Reductant Solution Fe (ppm) 2240 2240 2240 2240 2240 2240 2240 2240
2240 Ascorbate (mM) 20.8 20.8 8.3 8.3 8.3 8.3 20.8 20.8 20.8
Macromer (%) 9 6 9 6 8 11.5 9 9 6 Comonomer (%) -- 3 5 5 5 5 -- --
-- Contrast (%) 30 30 20 45 30 30 30 30 -- Viscosity (cp) 33.9 32.6
33.6 29.3 33.5 36.7 34 32.7 13.5 Oxidant Solution Peroxide (ppm)
150 250 200 250 250 250 250 250 150 Buffer (mM) 100 100 100 100 100
100 100 100 100 Macromer (%) 9 9 6 6 8 11.5 9 9 6 Comonomer (%) --
-- 3 5 5 5 -- -- -- Dequest .RTM. (ppm) 100 100 100 100 100 100 100
100 100 Contrast (%) 30 30 50 45 30 30 30 30 30 Viscosity (cp) 34.6
32.5 31.0 29.6 34.6 36.2 32.8 33.4 12.9 J K L M N O P Reductant
Solution Fe (ppm) 2240 2240 2240 2240 2240 2240 2240 Ascorbate (mM)
8.3 8.3 8.3 8.3 8.3 8.3 8.3 Macromer (%) 6 9 6 9 6 6 6 Comonomer
(%) 3 5 3 5 5 5 5 Contrast (%) 30 -- 30 -- 30 30 30 Viscosity (cp)
16.3 18.3 14.8 18.2 17.0 16.7 16.7 Oxidant Solution Peroxide (ppm)
200 200 250 250 250 250 250 Buffer (mM) 100 100 100 100 100 100 100
Macromer (%) 6 6 6 6 6 6 6 Comonomer (%) 3 3 3 3 5 5 5 Dequest
.RTM. (ppm) 100 100 100 100 100 100 100 Contrast (%) 30 30 30 30 30
30 30 Viscosity (cp) 15.0 15.6 14.8 15.1 17.1 16.8 16.5
TABLE-US-00002 TABLE 2 Results of Example 1 Injection volume
Injection time Flow In vitro gel time (ml) (sec) Occlusion? (sec) A
1.0 65 Yes 1.75 B 0.8 15 Yes 1.2 C 0.5 12 Yes 0.82 D 0.8 14 Yes
0.70 E 0.8 n.d. Yes 0.74 F 0.5 12 Yes 0.75 G 0.5 10 Yes 1.2 H 0.9
14 Yes 1.23 I 1.4 45 Yes 2.79 J 1.6 45 Yes 1.15 K 1.4 20 No 0.87 L
1.4 20 Yes 0.79 M 1.4 32 No 0.85 N 0.8 17 No 0.68 O 3.2 45 Yes 0.85
P 1.6 18 Yes 0.79
The liquid embolic compositions were easily injected through the
catheter and easily visualized by fluoroscopy. The compositions
flowed into small distal vessels within the kidneys before
gelation. By fluoroscopy, the polymer following injection was
located homogenously within the renal vasculature with small
arteries being filled. No polymer was seen in the renal vein for
any of the samples except K, M, and N.
Example 2
Microsphere Embolic Compositions
General Method of Making Microspheres:
300 ml of 1,2-dichloroethane (DCE) or paraffin was placed into a
500 ml dented kettle and stirred with a glass stir rod. Stabilizer
was added (either cellulose acetate butyrate (CAB) or dioctyl
sulfosuccinate (DOS) (the percent reported is based on the amount
of DCE used)) while stirring until dissolved. Once all of the
stabilizer was dissolved, stirring was ceased, and nitrogen was
bubbled through the solution for 10 minutes.
The macromer solution as described in Table 3 (between 10-30% sol
ids) was placed in a 100 ml flat-bottomed flask and stirred. 0.5%
potassium persulfate was added (based on amount of DCE or paraffin
used) to the macromer while stirring. Once the persulfate was
dissolved, nitrogen was bubbled through the solution for 5
minutes.
The macromer solution was added to the DCE or paraffin solution
dropwise, while stirring at 400 rpm. Once all of the macromer
solution was added, a small positive pressure of nitrogen was
applied. 0.5% N,N,N,N tetramethylethylenediamine (based on amount
of DCE or paraffin used) was added to the solution. The solution
was lowered into an oil bath at a temperature of 55.degree. C. and
allowed to react for three hours.
After three hours, the heat was removed and stirring was continued.
Once cooled, the DCE or paraffin was vacuum filtered off, and the
product was washed with DCE and acetone. The product was soaked in
acetone for 30 minutes, the acetone was decanted off, and the
product was soaked in water for at least 30 minutes. The water was
vacuum filtered off the product. The microspheres were sonicated
for 30 minutes and sieved into the desired size ranges of greater
than 850 microns, between 850 and 500 microns, between 500 and 250
microns, and smaller than 250 microns. The macromer used in samples
A through G had a PVA backbone (14 kDa, 12% acetate incorporation)
modified with 0.45 meq/g N-acrylamidoacetaldehyde dimethyl acetal
pendant polymerizable groups (about 6.3 crosslinks per chain). The
macromer used in sample H had a backbone of PVA 8-88 (67 kDa, 12%
acetate incorporation) modified with N-acrylamidoacetaldehyde
dimethyl acetal pendant polymerizable groups (about 7 crosslinks
per chain). The macromer used in sample I had a backbone of PVA
4-88 (31 kDa, 12% acetate incorporation) modified with
N-acrylamidoacetaldehyde dimethyl acetal pendant polymerizable
groups (about 7 crosslinks per chain). The stir speed was 400 rpm
except for sample G which was 350 rpm.
TABLE-US-00003 TABLE 3 Preparation of Microspheres Size
Distribution (microns) Sam- Macro- Yield 850- 500- ple mer (%)
Stabilizer (%) >850 500 250 <250 A 20 0.8% CAB in DCE 101 0 3
80 17 B 20 0.5% CAB in DCE 115 34 41 19 6 C 30 1% DOS in paraffin
41 nd nd nd nd D 30 1% DOS in paraffin 134 16 60 19 5 E 20 1% CAB
in DCE 96 0 14 72 13 F 20 0.8% CAB in DCE 96 0 32 57 11 G 10 0.8%
CAB in DCE 96 3 0 22 76 H 11 0.8% CAB in DCE 150 0 10 84 6 I 20
0.8% CAB in DCE 92 6 60 31 3
The microsphere products had very little aggregates (except for
sample D) and were mostly or all spherical.
Modifications and variations of the present invention will be
apparent to those skilled in the art from the forgoing detailed
description. All modifications and variations are intended to be
encompassed by the following claims. All publications, patents, and
patent applications cited herein are hereby incorporated by
reference in their entirety.
* * * * *
References